Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
72 participants
OBSERVATIONAL
2016-02-18
2017-05-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
However, strong inter-individual variations of this prevalence of sarcopenia exists. The key issue is to understand why the biological aging of the skeletal muscle is so different between people.
In this study, mechanisms involved in biological aging of the skeletal muscle in aging people (same chronological age) will be specified.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
However, strong inter-individual variations of this prevalence of sarcopenia exists. Some elderly (60 years old) reveal a biological aging of 80 years old, whereas 60 years old people reveal a biological aging of 60 years old. The key issue is to understand why the biological aging of the skeletal muscle is so different between people.
Previous sarcopenia studies in Humans did not really focus on chronological aging, they were all based on a comparison between young and old people. No study considered inter-individual modifications (biological aging) in sarcopenia. Furthermore, few studies were associated in the same study to "omic", histological, and epigenetic data, to obtain integrated point of view of Human Sarcopenia.
In this study, mechanisms involved in biological aging of the skeletal muscle in aging people (same chronological age) will be specified.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Proof cohort : muscular assessment
* Clinical examination : Body weight, BMI, cardiac frequency, muscular examination,...
* Blood appraisal : glycaemia, lipidic appraisal, leptin, albumin, coagulation, metabolome and epigenetic tests,...
* Urinary collection : metabolome tests
* Maximal voluntary quadriceps strength (MVC)
* Checking muscle functional skills
* Muscular biopsy
Proof cohort : muscular assessment
Clinical examination, blood appraisal, urinary collection, MVC, checking muscle functional skills and muscular biopsy will be performed.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Proof cohort : muscular assessment
Clinical examination, blood appraisal, urinary collection, MVC, checking muscle functional skills and muscular biopsy will be performed.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Between 80 and 83 years old
* Informed consent signed
* Genetic analyses consent signed
* Subject affiliated or entitled to a social security scheme
Exclusion Criteria
* Severe obesity (\>35)
* All chronic pathology requiring a treatment
* Severe renal insufficiency (discovery less than 6 months)
* Abnormal coagulation appraisal
* Allergy to local anesthetics
* Installation of a prosthetic hip and / or knee in the last six months
* Senile dementia
* Refusal of genetic study
80 Years
83 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ecole Nationale Superieure Lyon
UNKNOWN
Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
OTHER
Region Rhone Alpes
UNKNOWN
Centre Hospitalier Universitaire de Saint Etienne
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
FEASSON Léonard, MD
Role: PRINCIPAL_INVESTIGATOR
CHU SAINT-ETIENNE
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chu Saint Etienne
Saint-Etienne, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Barthelemy JC, Pichot V, Dauphinot V, Celle S, Laurent B, Garcin A, Maudoux D, Kerleroux J, Lacour JR, Kossovsky M, Gaspoz JM, Roche F. Autonomic nervous system activity and decline as prognostic indicators of cardiovascular and cerebrovascular events: the 'PROOF' Study. Study design and population sample. Associations with sleep-related breathing disorders: the 'SYNAPSE' Study. Neuroepidemiology. 2007;29(1-2):18-28. doi: 10.1159/000108914.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2015-A01484-45
Identifier Type: OTHER
Identifier Source: secondary_id
1508145
Identifier Type: -
Identifier Source: org_study_id